Analyzing Xcorporeal (OTCMKTS:XCRP) & CVRx (NASDAQ:CVRX)

CVRx (NASDAQ:CVRX) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Insider and Institutional Ownership

75.3% of CVRx shares are owned by institutional investors. 18.9% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for CVRx and Xcorporeal, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1	0	1	1	2.67
Xcorporeal	0	0	0	0	0.00

CVRx currently has a consensus price target of $11.50, suggesting a potential upside of 118.26%. Given CVRx’s stronger consensus rating and higher probable upside, equities analysts plainly believe CVRx is more favorable than Xcorporeal.

Valuation and Earnings

This table compares CVRx and Xcorporeal”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65 million	2.47	-$53.31 million	($2.02)	-2.61
Xcorporeal	N/A	N/A	N/A	N/A	N/A

Xcorporeal has lower revenue, but higher earnings than CVRx.

Profitability

This table compares CVRx and Xcorporeal’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVRx	-89.14%	-120.76%	-48.38%
Xcorporeal	N/A	N/A	N/A

Summary

CVRx beats Xcorporeal on 7 of the 10 factors compared between the two stocks.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Xcorporeal

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.